Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of administering obinutuzumab as a
single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE)
chemotherapy and determine the response rate of this treatment for children, adolescents and
young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).